- Home
- NBP vs DIAX Comparison
NBP vs DIAX Comparison
Compare NBP & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBP | DIAX |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.8M | 561.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBP | DIAX |
|---|---|---|
| Price | $3.27 | $15.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 989.3K | 96.6K |
| Earning Date | 04-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $12.80 |
| 52 Week High | $6.79 | $15.12 |
Technical Indicators
Market Signals| Indicator | NBP | DIAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 50.85 |
| Support Level | $3.71 | $15.36 |
| Resistance Level | $4.08 | $15.60 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 2.38 | 36.17 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.